New statement released by anticoagulation forum

New statement released by anticoagulation forum
The Anticoagulation Forum has endorsed a new consensus statement aimed at optimizing the delivery of anticoagulation therapy to inpatients; the statement has been published in the May issue of the Annals of Pharmacotherapy.

(HealthDay)—The Anticoagulation Forum has endorsed a new consensus statement aimed at optimizing the delivery of anticoagulation therapy to inpatients; the statement has been published in the May issue of the Annals of Pharmacotherapy.

Edith A. Nutescu, Pharm.D., from the University of Illinois at Chicago, and colleagues from the Anticoagulation Forum reviewed the medical literature to identify published articles relating to the standards of practice, national guidelines, patient safety initiatives, and regulatory requirements pertaining to anticoagulant use in the inpatient setting.

The recommendations endorsed by the Anticoagulation Forum and included in the statement are aimed at informing the development of coordinated care systems containing elements with demonstrated benefit in improvement of outcomes. The paper addresses the areas of process, accountability, integration, standards of practice, provider education and competency, patient education, care transitions, and outcomes.

"This document provides consensus guidelines for anticoagulant therapy in the inpatient setting and serves as a companion document to prior guidelines relevant for outpatients," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

New blood-thinner measures may cut medication errors

May 22, 2013

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Recommended for you

Supercomputers link proteins to drug side effects

17 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments